Educational resource · Updated September 2026

The Science of Tirzepatide

A clear, research-oriented guide to the dual GIP/GLP-1 receptor agonist used in metabolic medicine—mechanism, clinical trial context, and safety framing. Not medical advice.

Learn the basics SURMOUNT evidence

How tirzepatide works

Dual-receptor mechanism

Tirzepatide activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This dual incretin pathway is distinct from single-receptor GLP-1 agonists and is studied for effects on insulin secretion, glucagon, appetite, and gastric emptying in clinical programs.

SURMOUNT clinical context

In the SURMOUNT Phase 3 program (adults with obesity or overweight plus comorbidity, without type 2 diabetes in SURMOUNT-1), once-weekly tirzepatide plus lifestyle intervention was associated with substantial average body-weight reductions over 72 weeks versus placebo—on the order of roughly 15–21% depending on dose in published SURMOUNT-1 analyses. Individual results vary; trials are not a guarantee of personal outcomes.

FDA-approved brand names

In the United States, tirzepatide is available as FDA-approved brand medicines from Eli Lilly: Mounjaro® (type 2 diabetes indication) and Zepbound® (chronic weight management, and later an obstructive sleep apnea indication in adults with obesity). This site is independent and is not affiliated with or endorsed by Eli Lilly.

Compounded products: Compounded tirzepatide preparations are not FDA-approved. They are not reviewed by the FDA for safety, effectiveness, or quality in the same way as approved brand drugs. Regulatory context around compounding after national shortage resolutions continues to evolve—discuss options only with a licensed clinician.

Beyond weight change

Published research and label-supported programs have examined metabolic and related outcomes that may include glycemic measures, blood pressure, sleep apnea endpoints in indicated populations, and cardiometabolic markers. These findings come from specific trial designs and populations; they do not mean tirzepatide “cures” obesity, diabetes, or related conditions.

Explore topics

SURMOUNT evidence

What key trials reported—educational summary.

 Side effects & cautions

Common GI effects, boxed warning context, who should discuss risks.

 Compounded vs Zepbound®

Approval status, quality differences, 2026 regulatory notes.

 Cost without insurance

Cash-pay and telehealth pricing concepts—dated ranges.

About this hub

Tirzepatide Hub is an independent informational site. We summarize publicly available clinical and regulatory information so readers can ask better questions of their clinicians. Content is educational only and does not diagnose, prescribe, or replace professional care. Editorial review is ongoing; always verify details against current FDA labeling and your clinician’s guidance.